US drug developer MacroGenics (Nasdaq: MGNX) yesterday announced the achievement of $100 million in milestones from Incyte Corp (Nasdaq: INCY) related to development progress of Zynyz (retifanlimab-dlwr), following an agreement on July 24, 2024, pursuant to es were deemed to have been met.
Zynyz is an intravenous PD-1 inhibitor indicated in the US for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. The drug was approved by the US Food and Drug Administration (FDA) in March last year.
Zynyz is a monoclonal antibody initially developed by MacroGenics and licensed to Incyte under a 2017 exclusive global collaboration and license agreement. Incyte and its collaborators continue to pursue development of retifanlimab in other indications, which include both monotherapy and combination regimens.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze